LVAD Monitoring App Recall; ADHD Drug & CVD Risk; Value of ATTR Treatments?

The FDA announced the class I recall of an Abbott app used to monitor patients using the HeartMate 3 Left Ventricular Assist Device (LVAD), as well as updated guidance related to the troublesome “Stop Pump” command; the recall is a correction rather than a product removal.

Patients prescribed methylphenidate for attention deficit-hyperactivity disorder (ADHD) had a small signal for short-term increased cardiovascular risk. (JAMA Network Open)

Breaking from a highly sedentary lifestyle to take 9,000 to 10,000 steps daily was associated with cardiovascular benefit. (British Journal of Sports Medicine)

The Institute for Clinical and Economic Review said it will review three treatments for transthyretin amyloidosis (ATTR) cardiomyopathy: acoramidis, tafamidis (Vyndamax), and vutrisiran (Amvuttra).

In evaluating transthyretin amyloidosis, a worse amyloid burden went hand in hand with worse results on cardiopulmonary exercise testing, a cohort study found. (JAMA Cardiology)

A CDC study showed that from 2017 to 2021, the overall prevalence of adult hypertension was unchanged but antihypertensive medication use rose slightly from 60% to 63%. (Morbidity and Mortality Weekly Report)

Black people did not show as strong a link between sleep apnea and stroke in a population-based cohort study. (Neurology)

In a 5-year follow-up of the EXCEL trial, hospital readmission rates gave surgery the upper hand over angioplasty for revascularization for left main coronary disease. (Journal of the American College of Cardiology)

A pooled analysis of four trials showed the clinical tradeoffs of treating patients with left main disease with percutaneous coronary intervention (PCI) or coronary artery bypass grafting. (Circulation)

High remnant cholesterol predicted mortality in people with ST-segment elevation myocardial infarction undergoing PCI. (European Journal of Preventive Cardiology)

The PCSK9 inhibitor alirocumab (Praluent) was FDA approved for LDL cholesterol reduction in children ages 8 years and older with heterozygous familial hypercholesterolemia, Regeneron announced.

Over half of Native American teens and young adults had high cholesterol in a prospective cohort study. (Journal of the American Heart Association)

Bodyport said that with its congestion biomarker-based cardiac scale for remote heart failure monitoring, more heart failure events could be detected as compared with standard of care.

Certain markers may identify people with heart failure more likely to benefit from intravenous iron for iron deficiency, based on the IRONMAN trial. (European Heart Journal)

WhiteSwell announced that its catheter-based eLym therapy, in conjunction with loop diuretics, was associated with reduced tissue congestion in people with acute decompensated heart failure in the DELTA-HF study.

Using a single catheter for ablating premature ventricular complexes led to faster procedures with less radiation exposure and similar success rates. (Clinical Cardiology)

Please enable JavaScript to view the

comments powered by Disqus.